-
1دورية أكاديمية
المؤلفون: Lakhani, Nehal J1 (AUTHOR), Chow, Laura Q M2,3 (AUTHOR), Gainor, Justin F4 (AUTHOR), LoRusso, Patricia5 (AUTHOR), Lee, Keun-Wook6 (AUTHOR), Chung, Hyun Cheol7 (AUTHOR), Lee, Jeeyun8 (AUTHOR), Bang, Yung-Jue9 (AUTHOR), Hodi, Frank Stephen10 (AUTHOR), Kim, Won Seog8 (AUTHOR), Santana-Davila, Rafael2 (AUTHOR), Fanning, Philip11 (AUTHOR), Squifflet, Pierre12 (AUTHOR), Jin, Feng11 (AUTHOR), Kuo, Tracy C11 (AUTHOR), Wan, Hong I11 (AUTHOR), Pons, Jaume11 (AUTHOR), Randolph, Sophia S1,11 (AUTHOR) srandolph@alxoncology.com, Messersmith, Wells A13 (AUTHOR)
المصدر: Lancet Oncology. Dec2021, Vol. 22 Issue 12, p1740-1751. 12p.
مصطلحات موضوعية: *ESOPHAGEAL cancer, *TRASTUZUMAB, *PEMBROLIZUMAB, *ADVERSE health care events, *ANTINEOPLASTIC agents, *ESOPHAGOGASTRIC junction, *THERAPEUTIC use of antineoplastic agents, *RESEARCH, *IMMUNOGLOBULINS, *DRUG dosage, *CLINICAL trials, *RESEARCH methodology, *MONOCLONAL antibodies, *PROGNOSIS, *MEDICAL cooperation, *EVALUATION research, *COMPARATIVE studies, *TUMORS, *LONGITUDINAL method, *DRUG toxicity
مصطلحات جغرافية: SOUTH Korea
-
2دورية أكاديمية
المؤلفون: Creelan, Benjamin C., Yeh, Tammie C., Kim, Sang-We, Nogami, Naoyuki, Kim, Dong-Wan, Chow, Laura Q. M., Kanda, Shintaro, Taylor, Rosemary, Tang, Weifeng, Tang, Mei, Angell, Helen K., Roudier, Martine P., Marotti, Marcelo, Gibbons, Don L.
المصدر: British Journal of Cancer; 2021, Vol. 124 Issue 2, p383-390, 8p
مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, LUNG cancer, RESEARCH, GENETIC mutation, RESEARCH methodology, LUNG tumors, MONOCLONAL antibodies, CELL receptors, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies
-
3دورية أكاديمية
المؤلفون: Plimack, Elizabeth R1 elizabeth.plimack@fccc.edu, Bellmunt, Joaquim2, Gupta, Shilpa3, Berger, Raanan4, Chow, Laura Q M5, Juco, Jonathan6, Lunceford, Jared6, Saraf, Sanatan6, Perini, Rodolfo F6, O'Donnell, Peter H7, O'Donnell, Peter H7 (AUTHOR)
المصدر: Lancet Oncology. Feb2017, Vol. 18 Issue 2, p212-220. 9p.
مصطلحات موضوعية: *TRANSITIONAL cell carcinoma, *PEMBROLIZUMAB, *MEDICATION safety, *LIGANDS (Biochemistry), *CYTOLOGY, *RANDOMIZED controlled trials, *THERAPEUTICS, *ANTINEOPLASTIC agents, *THERAPEUTIC use of monoclonal antibodies, *CANCER relapse, *CLINICAL trials, *COMPARATIVE studies, *LONGITUDINAL method, *RESEARCH methodology, *MEDICAL cooperation, *METASTASIS, *PROGNOSIS, *RESEARCH, *SAFETY, *SURVIVAL, *TUMOR classification, *URINARY organs, *EVALUATION research, *TUMORS
-
4دورية أكاديمية
المؤلفون: Kim, Dong-Wan1, Mehra, Ranee2, Tan, Daniel S W3, Felip, Enriqueta4, Chow, Laura Q M5, Camidge, D Ross6, Vansteenkiste, Johan7, Sharma, Sunil8, De Pas, Tommaso9, Riely, Gregory J10, Solomon, Benjamin J11, Wolf, Jürgen12, Thomas, Michael13, Schuler, Martin14, Liu, Geoffrey15, Santoro, Armando16, Sutradhar, Santosh17, Li, Siyu17, Szczudlo, Tomasz17, Yovine, Alejandro18
المصدر: Lancet Oncology. Apr2016, Vol. 17 Issue 4, p452-463. 12p.
مصطلحات موضوعية: *ANAPLASTIC lymphoma kinase, *NON-small-cell lung carcinoma, *PROTEIN-tyrosine kinase inhibitors, *ANTINEOPLASTIC agents, *METASTASIS, *CANCER treatment, *PATIENTS, *BLOOD-brain barrier, *CLINICAL trials, *COMPARATIVE studies, *DRUG resistance in cancer cells, *GENES, *HETEROCYCLIC compounds, *LUNG cancer, *RESEARCH methodology, *MEDICAL cooperation, *PROGNOSIS, *RESEARCH, *RESEARCH funding, *SULFONES, *TRANSFERASES, *EVALUATION research, *PROTEIN kinase inhibitors